The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences
Tomas Frymann, Sophie Whitney, David B. Yaden, Joshua Lipson
Frontiers in Psychology May 23, 2022 DOI: 10.3389/fpsyg.2022.863247 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Scale development and validation study Peer reviewed |
|---|---|
| Keywords | Confirmatory factor analysis Scale ratio Construct validity Exploratory factor analysis Convergent validity Content validity Face validity Psychometrics Structural equation modeling Clinical psychology Internal consistency |
| Citations | 26 |
| Key points | The Integration Engagement Scale and Experienced Integration Scale are valid and reliable measurements of behavioral and experiential forms of psychedelic integration. |
Abstract
In this study, we describe the development and initial validation of two psychometric scales for measuring psychedelic integration. Psychedelic integration refers to the post-acute period of time following psychedelic drug administration. We created the Integration Engagement Scale (IES) to capture positive behavioral engagement with integration and the Experienced Integration Scale (EIS) to capture internal aspects of feeling integrated. These scales were developed to measure post-acute psychedelic administration dynamics in order to inform the creation of enhanced integration support and to help refine a general conceptual understanding of the construct of psychedelic integration. The scales are brief and face valid instruments designed for practical use in applied and research settings. Scale items were generated and refined using the Iterative Process Model of scale development, with input from psychedelics experts and clinicians. Content validity, internal structure, and reliability were assessed via expert surveys, content validity analysis, cognitive interviewing, convergent validity analysis, exploratory factor analysis, and confirmatory factor analysis. The data indicates the scales are valid and reliable measurements of the behavioral and experiential forms of Psychedelic Integration.
Citations in the library
Cited by 26
- Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics Journal of Psychopharmacology November 16, 2023
- From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS). Scientific Reports January 29, 2025
- Set and Setting for Psychedelic Harm Reduction Psychedelic Harm Reduction 2026
- Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial. BMC Psychiatry January 26, 2024
- Key competencies for psychedelic treatment in real-world mental health care settings. General Hospital Psychiatry 2025
and 21 more in the library
Cites 63
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
and 58 more in the library